SCHEMBL4319857

SCHEMBL4319857

O=C(Nc1ccccc1C=Cc1n[nH]c2ccccc12)c1sccc1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ EPHB3 P54753 1/20 0.47
▸ AURKA O14965 3/20 0.46
▸ AURKB Q96GD4 3/20 0.46
▸ KDR P35968 5/20 0.42
▸ CASP3 P42574 2/20 0.40
▸ SENP8 Q96LD8 2/20 0.40
▸ SENP7 Q9BQF6 2/20 0.40
▸ SENP6 Q9GZR1 2/20 0.40
▸ SNCA P37840 4/20 0.40
▸ JAK2 O60674 2/20 0.39
▸ JAK1 P23458 2/20 0.39
▸ GAA P10253 2/20 0.38
▸ PKM P14618 1/20 0.38
▸ PRSS12 P56730 1/20 0.38
▸ CHEK1 O14757 2/20 0.37
▸ BMPR1B O00238 1/20 0.37
▸ PLK4 O00444 1/20 0.37
▸ STK25 O00506 1/20 0.37
▸ CIT O14578 1/20 0.37
▸ RIOK3 O14730 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4319852 1.00 EPHB3 (0.47) EPHB3AURKAAURKBKDRCASP3
SCHEMBL4313350 0.88 AURKA (0.56) EPHB3AURKAAURKBKDRSNCA
SCHEMBL4313356 0.88 AURKA (0.56) EPHB3AURKAAURKBKDRSNCA
SCHEMBL4308251 0.87 AURKA (0.47) EPHB3AURKAAURKBKDRSNCA
SCHEMBL4308257 0.87 AURKA (0.47) EPHB3AURKAAURKBKDRSNCA
SCHEMBL4314371 0.82 MAPT (0.47) EPHB3AURKAAURKBKDRCASP3
SCHEMBL4314375 0.82 MAPT (0.47) EPHB3AURKAAURKBKDRCASP3
SCHEMBL4314478 0.81 AURKA (0.43) EPHB3AURKAAURKBKDRSNCA
SCHEMBL4314473 0.81 AURKA (0.43) EPHB3AURKAAURKBKDRSNCA
SCHEMBL4315179 0.80 KDR (0.59) EPHB3KDRSNCAJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7605272-B2 IGF-1R inhibitor KYOWA HAKKO KIRIN CO., LTD. (JP) 2009-10-20 — — US disclosed
US-20090054508-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2009-02-26 — — US disclosed
EP-1847532-A1 IGF-1R INHIBITOR KYOWA HAKKO KOGYO CO., LTD. (JP) 2007-10-24 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054508-A1 IGF-1R INHIBITOR IGF1R, IGFBP5, IGFBP1 EPHB3 3547/4885AURKA 3687/4885AURKB 3438/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback